The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $83.44

Today's change-2.52 -2.93%
Updated February 11 4:02 PM EST. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $83.44

Today's change-2.52 -2.93%
Updated February 11 4:02 PM EST. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc down (U.S.)$2.52

Valeant Pharmaceuticals International Inc closed sharply lower Thursday, dropping (U.S.)$2.52 or 2.93% to (U.S.)$83.44. Over the last five days, shares have lost 13.93% and are down 17.91% for the last year to date. This security has underperformed the S&P 500 by 37.65% during the last year.

Key company metrics

  • Open(U.S.) $83.76
  • Previous close(U.S.) $85.96
  • High(U.S.) $85.13
  • Low(U.S.) $79.62
  • Bid / Ask-- / --
  • YTD % change-17.91%
  • Volume7,128,622
  • Average volume (10-day)7,117,842
  • Average volume (1-month)6,893,896
  • Average volume (3-month)12,938,599
  • 52-week range(U.S.) $69.33 to (U.S.) $263.81
  • Beta0.70
  • Trailing P/E47.23×
  • P/E 1 year forward8.37×
  • Forward PEG0.40×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $1.77
Updated February 11 4:02 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+6.09%

Valeant Pharmaceuticals International Inc has a net profit margin of 6.09%. This is comparable to other companies in this industry group.
Company Books

S&P TSX0.81%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue2,7872,7322,1912,280
Total other revenue--------
Total revenue2,7872,7322,1912,280
Gross profit2,1392,0471,6161,690
Total cost of revenue648685575590
Total operating expense2,3392,3911,6681,672
Selling / general / administrative698686574525
Research & development102815659
Depreciation / amortization67958536586
Interest expense (income), net operating--------
Unusual expense (income)18217792406
Other operating expenses, total3017767
Operating income448342523608
Interest income (expense), net non-operating-420-413-298-225
Gain (loss) on sale of assets--------
Other--------
Income before tax-6-65155590
Income after tax52-5275534
Income tax, total-57-138156
Net income50-5374535
Total adjustments to net income--------
Net income before extra. items50-5374535
Minority interest-2-1-11
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items50-5374535
Inc. avail. to common incl. extra. items50-5374535
Diluted net income50-5374535
Dilution adjustment----00
Diluted weighted average shares351344343342
Diluted EPS excluding extraordinary itemsvalue per share0.14-0.150.211.56
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.570.190.342.82